Skip to main content
TipRanks
Go Ultimate75% OFF

Thermo Fisher (TMO) AI Stock Analysis

5,312 Followers
TMO

Thermo Fisher

(NYSE:TMO)

Select Model
Rating:76.9Outperform
Price Target:$780.00â–²(12.83% Upside)
Action:reiterated
Date:10/21/26

The score is driven primarily by strong financial quality and cash generation, supported by a clearly bullish technical trend and a very positive, guidance-raising earnings call. These strengths are partially offset by a high valuation (P/E 36.915) and meaningful leverage, alongside pockets of uneven demand (e.g., flat academic/government and muted reagent environment).

Positive Factors
Diversified recurring-revenue modelRevenue combines repeat-purchase consumables, service contracts and workflow products with instruments that generate downstream pull-through. This mix, spanning pharma, research, clinical and industrial customers, supports recurring demand and reduces reliance on any single end market.
Negative Factors
Meaningful leverageMeaningful debt and elevated leverage increase fixed financial obligations and reduce flexibility relative to a lightly levered balance sheet. They can constrain capital allocation and make the company more sensitive to slower growth, refinancing conditions or sustained interest expense.

Thermo Fisher Key Performance Indicators (KPIs)

Operating Income by SegmentShows the profitability of different business segments, highlighting which areas are driving earnings and where there may be opportunities or challenges.

$0.00$1.00B$2.00B$3.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Life Sciences Solutions has re-based well below its pandemic-era peaks and is only marginally recovering, so it no longer singularly drives Thermo Fisher’s profitability; instead, Laboratory Products and Analytical Instruments have materially grown their operating-income share—Analytical Instruments in particular shows sharp margin uplift—supporting the company’s raised guidance and margin expansion. That momentum is reinforced by recent acquisitions and product launches, but the microbiology divestiture, reduced FX tailwind and elevated leverage temper near-term EPS upside.

Data provided by:The Fly

Thermo Fisher (TMO) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%30%TMO+20.91%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$256.15B
Dividend Yield
0.27%
Average Volume (3M)
2.16M
Price to Earnings (P/E)
36.4
Beta (1Y)
0.72
Revenue Growth
8.27%
EPS Growth
9.59%
Country
US
Employees
125,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Thermo Fisher Business Overview & Revenue Model

Company Description

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio o...

How the Company Makes Money

Thermo Fisher makes money by selling a mix of recurring consumables/services and higher-ticket capital equipment, primarily to pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laborator...

Thermo Fisher Earnings Call Summary

Earnings Call Date:Oct 21, 2026(Q3-2026)|% Change Since:0.58%|Next Earnings Date:Feb 04, 2027
Earnings Call SentimentPositive

The call was strongly positive. Thermo Fisher delivered broad-based revenue, profit, margin, cash flow, and organic growth improvements; exceeded prior guidance; raised full-year revenue, EPS, and free cash flow guidance; and reported continued momentum in pharma, biotech, analytical instruments, AI, clinical research, and bioproduction. The main challenges were flat academic and government revenue, a decline in reported Specialty Diagnostics revenue, muted reagent demand, unfavorable mix, and some Pharma Services timing between the third and fourth quarters.

Positive Updates

Strong Third-Quarter Financial Performance
Revenue grew 9% year over year to $12.14 billion, adjusted operating income increased 15% to $2.97 billion, adjusted operating margin expanded by 120 basis points to 24.5%, and adjusted EPS grew 15% to $6.68. GAAP EPS was $4.64, up 9%.

Negative Updates

Academic and Government Revenue Was Flat
Revenue in the academic and government end market was flat during the quarter, although management noted good performance in chromatography and mass spectrometry and continued demand for high-end instrumentation.

Company Guidance

For 2026, guidance is revenue of $47.7 billion-$48.2 billion, representing 7%-8% reported revenue growth over 2025 and full-year organic revenue growth of 4%; adjusted earnings per share is $25.13-$25.43 per share, representing 10%-11% growth; fourth-quarter organic revenue growth is expected to be 4%, with a year over year revenue tailwind from foreign exchange of approximately $200 million for the year; guidance assumes 80 basis points of adjusted operating income margin expansion, approximately $650 million of net interest expense, an adjusted income tax rate of 11.5%, between $1.9 billion and $2 billion of net capital expenditures, free cash flow between $7 billion and $7.5 billion, $4 billion of share buybacks, approximately $700 million of capital returned through dividends, and a full-year average diluted share count between 371 million and 372 million shares.

Thermo Fisher Financial Statement Overview

Summary

Fundamentals are solid, led by strong profitability (TTM gross margin ~41%, operating margin ~18.6%, net margin ~15.1%) and strong cash generation (TTM OCF $9.32B; FCF $7.60B; ~81% FCF-to-net-income). Offsets include post-2021 growth normalization (dip in 2023, modest 2024–2025 growth) and meaningful leverage (debt-to-equity ~0.81; debt $41.4B), with only moderate cash flow coverage (~0.60).

Income Statement

78Positive

Balance Sheet

74Positive

Cash Flow

81Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue47.35B44.56B42.88B42.86B44.91B39.21B
Gross Profit19.62B18.24B17.73B17.19B19.01B19.63B
EBITDA11.24B11.47B11.80B11.20B11.94B11.97B
Net Income7.08B6.74B6.33B6.00B6.95B7.72B
Balance Sheet
Total Assets114.23B110.34B97.32B98.73B97.15B95.12B
Cash, Cash Equivalents and Short-Term Investments6.06B10.11B5.58B8.08B8.52B4.48B
Total Debt41.37B39.38B32.77B36.42B36.07B36.34B
Total Liabilities59.47B56.81B47.65B51.88B53.01B54.15B
Stockholders Equity54.76B53.41B49.58B46.73B43.98B40.79B
Cash Flow
Free Cash Flow7.60B6.29B7.27B6.93B6.91B6.79B
Operating Cash Flow9.32B7.82B8.67B8.41B9.15B9.31B
Investing Cash Flow-7.98B-4.05B-5.84B-5.14B-2.16B-21.93B
Financing Cash Flow985.00M1.80B-6.79B-3.62B-2.81B6.58B

Thermo Fisher Technical Analysis

Technical Analysis SentimentNeutral
Last Price691.33

Price Trends

50DMA672.13Positive
100DMA621.21Positive
200DMA555.33Positive

Market Momentum

MACD9.19Positive
RSI50.55Neutral
STOCH53.66Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TMO, the sentiment is Neutral. The current price of 691.33 is below the 20-day moving average (MA) of 696.37, above the 50-day MA of 672.13, and above the 200-day MA of 555.33, indicating a neutral trend. The MACD of 9.19 indicates Positive momentum. The RSI at 50.55 is Neutral, neither overbought nor oversold. The STOCH value of 53.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TMO.

Thermo Fisher Risk Analysis

Thermo Fisher disclosed 26 risk factors in its most recent earnings report. Thermo Fisher reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

2 New Risks
1.A violation of data privacy laws could adversely harm our operating results and financial condition, damage our reputation or otherwise materially harm our business.Q4, 2023
2.Our success is largely dependent upon our ability to attract and retain a highly qualified workforce, comprised of scientific, technical, clinical, and management talent.Q4, 2023

Thermo Fisher Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TMO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IDXXIDXX82Outperform$55.20B47.3771.18%―11.87%17.33%
TMOTMO77Outperform$256.15B36.4013.31%0.27%8.27%9.59%
AA75Outperform$48.75B34.0120.47%0.59%8.60%19.07%
MTDMTD75Outperform$34.36B37.389999.00%―6.51%15.03%
DHRDHR73Outperform$161.75B37.788.18%0.66%5.52%25.53%
WATWAT59Neutral$44.56B192.940.81%―80.68%-78.49%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%TMOADHRIDXXMTDWATDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TMO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TMOThermo Fisher Scientific691.33117.3220.44%
AAgilent Technologies172.9230.1521.12%
DHRDanaher Corporation229.916.052.70%
IDXXIdexx Laboratories700.6530.444.54%
MTDMettler-toledo International1727.26330.8123.69%
WATWaters Corp453.4276.7920.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 21, 2026